The therapeutic uses of NOAC are increasing. NOACs are known to interfere with almost all coagulation tests to varying degrees and sometimes patients who need to be tested for underlying coagulation defects may also be on NOAC.
DOAC-Stop ™ is the first general agent available to solve diagnostic problems associated with NOACs.
After treatment with DOAC-Stop ™, plasma samples can be analyzed for underlying clotting defects such as factor deficiencies, heparin, lupus anticoagulant, or other interfering antibodies.